Al's Comment:

 xCures is running an expanded access program of this drug for any type of cancer that has  MAPK pathway-altered solid tumor(s), including but not limited to KRAS, NRAS, HRAS, BRAF, MEK, and ERK mutations who have incomplete response to or have exhausted available therapies.    Low grade gliomas have a high chance of having this mutation. Glioblastomas, Pancreatic Cancer, Colon cancer, Ovarian and more types of cancers also sometimes get this mutation. Check your pathology report for it.


Posted on: 11/24/2022

 Ulixertinib may change childhood brain tumor treatment


Click HERE to return to brain tumor news headlines.

Our privacy / cookie policy has changed.
Click HERE to read it!